• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Investment Advisor Says 'Throwing Random Darts At Tickers' Would Beat ARKK As Cathie Wood's Flagship Fund Lags Far Behind Soaring Market: 'How Do They Do It?!'

    5/20/24 6:51:09 AM ET
    $DNA
    $NVDA
    $SOFI
    $TSLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Semiconductors
    Technology
    Get the next $DNA alert in real time by email

    Ark Investment Management, led by star investor Cathie Wood, is facing a harsh reality in 2024. While the broader market is hitting record highs, Ark’s actively managed funds are lagging far behind, raising concerns about their future viability. One investment advisor has sounded a stark warning, suggesting Ark’s funds could even go under. 

    What Happened: Ram Ahluwalia of Lumida Wealth pointed to Ark’s flagship ETF, Ark Innovation ETF (NYSE:ARKK), which is currently trading over 70% below its all-time high, a stark contrast to the S&P 500’s recent record highs.

    ARKK had its heydays amid the recent pandemic as a significant share of its holdings were COVID-19 plays, which capitalized on lockdown restrictions and the work-from-home environment that prevailed at that time. The ETF peaked at $159.70 in mid-February 2021.

    Source: Benzinga

    Here are the year-to-performances of Ark’s key ETFs vs the broader market:

    ETFYTD Change
    ARKK-13.21%
    ARK Next Generation Internet ETF (NYSE:ARKW)+3.02%
    ARK Genomic Revolution ETF (CBOE: ARKG)-19.14%
    ARK Autonomous Technology & Robotics ETF (CBOE: ARKQ)-2.62%
    ARK Fintech Innovation ETF (NYSE:ARKF)+1.89%
    ARK Space Exploration & Innovation ETF (CBOE: ARKX)+1.23%
    SPDR S&P 500 ETF Trust (NYSE:SPY)+11.74%

    See Also: Best ETFs To Buy Right Now

    What Ails Ark Funds? Ahluwalia attributed Ark’s woes to a combination of missed bets and an over-reliance on “vision” over fundamentals. 

    He criticized Ark for selling Nvidia Corp. (NASDAQ:NVDA) stock early in the AI boom and pouring resources into companies like Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) and SoFi Technologies, Inc. (NASDAQ:SOFI). 

    “They sold Nvidia, bought Tesla (We did the opposite). They bought Ginko Biosciences (Never touched it),” he wrote. “They bought $SOFI (We shorted it).”

    He argued that Ark prioritizes chasing “future ideas” without proper evaluation of traction, valuation, and management credibility.

    This focus on disruptive innovation, a cornerstone of Ark’s strategy, seems to be backfiring in the current market. While Wood emphasizes long-term growth potential in areas like AI and robotics, many of Ark’s top holdings, including Tesla, Inc. (NASDAQ:TSLA), haven’t delivered the returns the firm anticipated.

    “The consistency & statistical significance of how consistently ARKK under-performs is truly incredible,” Ahluwalia said. “If someone asked me to design a product with that kind of performance profile, I don’t think I could do it.” 

    “Literally throwing random darts at tickers would out-perform ARKK,” he added. “How do they do it!?”

    Stock indices are at ATHs!

    Meanwhile $ARKK is 70% below its All Time High

    They sold Nvidia, bought Tesla (We did the opposite)

    They bought Ginko Biosciences (Never touched it)

    They bought $SOFI (We shorted it)

    The consistency & statistical significance of how consistently… https://t.co/0AgFLul8DK

    — Ram Ahluwalia CFA, Lumida (@ramahluwalia) May 16, 2024

    “Investing the assets of others is a special duty. The lives of others and their family goals are directly impacted,” Ahluwalia said. “Institutions that are chronic destroyers of wealth should absolutely be called out. Most people lack the skill to discern good from bad investing.”

    Different View: Morningstar strategist Robby Greengold offered another perspective on Ark’s struggles. He suggested the firm lacks the forecasting talent needed for its focus on unproven companies and criticizes the high portfolio correlation due to its thematic investment approach. He argued Ark’s portfolio essentially resembles a tech-heavy fund, despite its focus on disruptive innovation.

    Why It Matters: Wood’s Ark Invest reigned supreme in early 2021, managing a hefty $59 billion across its ETFs. Today, however, that figure has shrunk by 80% to a mere $11.1 billion, likely a consequence of rising interest rates dampening investor enthusiasm for Wood’s long-term tech bets.

    In Monday’s premarket session on Monday, ARKK rose 0.33% to $45.60, according to Benzinga Pro data.

    Read Next: Looking For Superlative Returns? Investor Flags Potential 30% Gains In This Sector After Warren Buffett Turns Market Focus Toward These Stocks

    Image made via photos on Flickr and Shutterstock

    Get the next $DNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA
    $NVDA
    $SOFI
    $TSLA

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    SoFi Technologies Inc.
    $SOFI
    2/9/2026$30.00Mkt Perform → Mkt Outperform
    Citizens
    SoFi Technologies Inc.
    $SOFI
    2/3/2026$31.00Neutral → Overweight
    Analyst
    SoFi Technologies Inc.
    $SOFI
    2/2/2026$36.00 → $33.00Buy
    Needham
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    NVIDIA Corporation
    $NVDA
    1/15/2026$240.00Outperform
    RBC Capital Mkts
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    More analyst ratings

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Rishel Jeremy

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    3/13/26 7:19:16 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Chief Risk Officer Pinto Arun

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    3/13/26 7:19:10 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by CFO and PAO Lapointe Christopher

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    3/13/26 7:19:06 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NVIDIA and Nebius Partner to Scale Full-Stack AI Cloud

    SANTA CLARA, Calif. and AMSTERDAM, March 11, 2026 (GLOBE NEWSWIRE) -- NVIDIA and Nebius Group N.V. (NASDAQ:NBIS) today announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius, reflecting NVIDIA's confidence in Nebius's business and unique depth of engineering expertise across the full AI technology stack. To help meet rapidly growing global demand for high-performance compute, the partnership deepens Nebius and NVIDIA's relationship across the full AI technology stack, from AI factory architecture to production software, enabling Nebius to accelerate the

    3/11/26 8:00:00 AM ET
    $NBIS
    $NVDA
    Computer Software: Programming Data Processing
    Technology
    Semiconductors

    Templum to Offer Premier Private Market Investment Opportunities in Perplexity AI, OpenAI, and Colossal Biosciences to SoFi Members

    Limited-time offering provides investors access to highly sought-after private market leaders NEW YORK, March 5, 2026 /PRNewswire/ -- Templum, a leading infrastructure provider for private markets and SoFi (NASDAQ:SOFI), the one-stop shop for digital financial services, today announced the launch of a limited-time private market investment window for accredited investors to access Colossal Biosciences, OpenAI, and/or Perplexity AI through the Cosmos Fund.  The three offerings will be available from March 5 through March 30, 2026, and repres

    3/5/26 9:15:00 AM ET
    $SOFI
    Finance: Consumer Services
    Finance

    BitGo Selected to Provide Stablecoin Infrastructure and Support Distribution for SoFiUSD

    BitGo Bank & Trust, N.A. ("BitGo Bank & Trust"), an OCC-regulated digital asset trust bank and subsidiary of BitGo Holdings, Inc. ("BitGo") (NYSE:BTGO), today announces that they have been selected to provide stablecoin infrastructure services and support distribution for SoFiUSD, a U.S. dollar-pegged stablecoin issued by SoFi Bank, N.A. SoFiUSD is the first stablecoin issued by the U.S. nationally chartered and insured deposit bank on a public, permissionless blockchain. Through its Stablecoin-as-a-Service platform, BitGo is providing technology and operational infrastructure supporting SoFi Bank's issuance of SoFiUSD. BitGo will also collaborate with select payments providers, market pa

    3/5/26 8:00:00 AM ET
    $BTGO
    $SOFI
    Finance: Consumer Services
    Finance

    $DNA
    $NVDA
    $SOFI
    $TSLA
    SEC Filings

    View All

    SEC Form 144 filed by NVIDIA Corporation

    144 - NVIDIA CORP (0001045810) (Subject)

    3/13/26 4:24:43 PM ET
    $NVDA
    Semiconductors
    Technology

    SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

    144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    3/11/26 10:14:18 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Tesla Inc.

    144 - Tesla, Inc. (0001318605) (Subject)

    3/6/26 5:42:03 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SoFi Technologies upgraded by Citizens with a new price target

    Citizens upgraded SoFi Technologies from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    2/9/26 6:58:53 AM ET
    $SOFI
    Finance: Consumer Services
    Finance

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Noto Anthony bought $1,001,515 worth of shares (56,000 units at $17.88), increasing direct ownership by 0.48% to 11,675,452 units (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    3/2/26 3:36:37 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    General Counsel Lavet Robert S bought $105,220 worth of shares (5,000 units at $21.04) (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    2/6/26 6:18:51 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    EVP GBUL Borrow Schuppenhauer Eric bought $99,650 worth of shares (5,000 units at $19.93), increasing direct ownership by 2% to 228,768 units (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    2/5/26 5:53:28 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Leadership Updates

    Live Leadership Updates

    View All

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    United Airlines Launches MileagePlus Debit Rewards Card that Earns Miles for Spending and Saving

    This new card allows MileagePlus members to earn miles through everyday purchases and qualifying account balances Available now with no monthly fees with an average daily account balance of $2,000 or greater, MileagePlus members can open the debit rewards card at UnitedDebitRewards.com CHICAGO, Nov. 4, 2025 /PRNewswire/ -- United Airlines today announced a new MileagePlus® Debit Rewards Card that offers cardmembers additional ways to earn miles through spending and saving – designed to make flying the world's largest airline* even more rewarding. As part of the launch, for a l

    11/4/25 8:00:00 AM ET
    $SOFI
    $UAL
    Finance: Consumer Services
    Finance
    Air Freight/Delivery Services
    Consumer Discretionary

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by NVIDIA Corporation

    SC 13G/A - NVIDIA CORP (0001045810) (Subject)

    11/12/24 10:32:12 AM ET
    $NVDA
    Semiconductors
    Technology

    $DNA
    $NVDA
    $SOFI
    $TSLA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

    Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe

    2/26/26 4:26:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026

    Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the previous quarter and up 73% from a year ago. For fiscal 2026, revenue was $215.9 billion, up 65% from a year ago. For the quarter, GAAP and non-GAAP gross margins were 75.0% and 75.2%, respectively. For fiscal 2026, GAAP and non-GAAP gross margins were 71.1% and

    2/25/26 4:31:17 PM ET
    $NVDA
    Semiconductors
    Technology

    Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a

    2/19/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care